The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a serotonin receptor (HTR) modulator, e.g. a HTR antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
